Codon
Executive Summary
West German firm Schering AG agrees to acquire all the outstanding common stock of the closely held, California-based biotechnology firm. The two companies have previously collaborated in the cardiovascular area. "Codon's development of anticoagulant proteins is especially promising," Schering AG said.